The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary arterial hypertension
See also under PMID 29329993
Publications
Palasset TL, Chaumais MC, Weatherald J, Savale L, Jaïs X, Price LC, Khouri C, Bulifon S, Seferian A, Jevnikar M, Boucly A, Manaud G, Pancic S, Chabanne C, Ahmad K, Volpato M, Favrolt N, Guillaumot A, Horeau-Langlard D, Prévot G, Fesler P, Bertoletti L, Re
Association between Leflunomide and Pulmonary Hypertension.
Annals of the American Thoracic Society 2021 Aug;18;1306-1315 — 2021 Aug — 1306-1315
Pulmonary arterial hypertension in four patients treated by leflunomide.
Joint, bone, spine : revue du rhumatisme 2018 Dec;85;761-763 — 2018 Dec — 761-763
Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report.
Cardiovascular toxicology 2012 Jun;12;180-3 — 2012 Jun — 180-3
Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide.
Rheumatology (Oxford, England) 2004 Nov;43;1451-3 — 2004 Nov — 1451-3